Ballentine Partners’s HCA Healthcare HCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.43M | Sell |
3,670
-49
| -1% | -$20.7K | 0.02% | 293 |
|
|
2026
Q1 | $1.76M | Buy |
3,719
+21
| +0.6% | +$10.6K | 0.02% | 225 |
|
|
2025
Q4 | $1.73M | Buy |
3,698
+5
| +0.1% | +$2.32K | 0.02% | 218 |
|
|
2025
Q3 | $1.57M | Buy |
3,693
+29
| +0.8% | +$11.2K | 0.02% | 243 |
|
|
2025
Q2 | $1.4M | Sell |
3,664
-399
| -10% | -$144K | 0.02% | 262 |
|
|
2025
Q1 | $1.4M | Sell |
4,063
-6
| -0.1% | -$1.93K | 0.02% | 236 |
|
|
2024
Q4 | $1.22M | Sell |
4,069
-44
| -1% | -$15.4K | 0.02% | 246 |
|
|
2024
Q3 | $1.67M | Buy |
4,113
+107
| +3% | +$39.2K | 0.03% | 198 |
|
|
2024
Q2 | $1.29M | Buy |
4,006
+127
| +3% | +$41.3K | 0.02% | 219 |
|
|
2024
Q1 | $1.29M | Buy |
3,879
+38
| +1% | +$11.6K | 0.02% | 203 |
|
|
2023
Q4 | $1.04M | Buy |
3,841
+675
| +21% | +$167K | 0.02% | 223 |
|
|
2023
Q3 | $779K | Sell |
3,166
-18
| -0.6% | -$4.92K | 0.02% | 231 |
|
|
2023
Q2 | $966K | Buy |
3,184
+81
| +3% | +$22.5K | 0.02% | 201 |
|
|
2023
Q1 | $818K | Buy |
3,103
+124
| +4% | +$31.5K | 0.02% | 222 |
|
|
2022
Q4 | $715K | Sell |
2,979
-26
| -0.9% | -$5.82K | 0.02% | 225 |
|
|
2022
Q3 | $553K | Buy |
3,005
+439
| +17% | +$87.5K | 0.02% | 231 |
|
|
2022
Q2 | $431K | Buy |
2,566
+38
| +2% | +$8.16K | 0.02% | 260 |
|
|
2022
Q1 | $634K | Buy |
2,528
+51
| +2% | +$12.8K | 0.02% | 228 |
|
|
2021
Q4 | $637K | Hold |
2,477
| – | – | 0.02% | 236 |
|
|
2021
Q3 | $601K | Buy |
2,477
+18
| +0.7% | +$4.4K | 0.02% | 212 |
|
|
2021
Q2 | $508K | Buy |
2,459
+6
| +0.2% | +$1.22K | 0.02% | 231 |
|
|
2021
Q1 | $462K | Sell |
2,453
-118
| -5% | -$20.8K | 0.02% | 233 |
|
|
2020
Q4 | $423K | Sell |
2,571
-396
| -13% | -$57.9K | 0.02% | 235 |
|
|
2020
Q3 | $370K | Buy |
2,967
+390
| +15% | +$48.3K | 0.02% | 249 |
|
|
2020
Q2 | $250K | Sell |
2,577
-61
| -2% | -$6.34K | 0.01% | 310 |
|
|
2020
Q1 | $238K | Buy |
2,638
+144
| +6% | +$18.6K | 0.01% | 289 |
|
|
2019
Q4 | $368K | Sell |
2,494
-5
| -0.2% | -$671 | 0.02% | 267 |
|
|
2019
Q3 | $301K | Sell |
2,499
-102
| -4% | -$13.2K | 0.01% | 291 |
|
|
2019
Q2 | $351K | Buy |
2,601
+1,004
| +63% | +$127K | 0.02% | 266 |
|
|
2019
Q1 | $209K | Buy |
+1,597
| New | +$214K | 0.01% | 305 |
|
|
2018
Q4 | – | Sell |
-1,603
| Closed | -$222K | – | 360 |
|
|
2018
Q3 | $222K | Buy |
+1,603
| New | +$200K | 0.01% | 317 |
|
Other funds holding HCA
Ballentine Partners's HCA Position: Q2 2026 in Review
Ballentine Partners reduced its HCA Healthcare (HCA) stake by 1.3% in Q2 2026, selling an estimated $20.7K and leaving 3,670 shares worth $1.43M. The position accounts for 0.02% of the portfolio, ranked #293.
Ballentine Partners first reported a position in HCA in Q3 2018 and has held it in 31 quarters since. The position peaked at $1.76M in Q1 2026. 1,339 funds tracked by Wall St. Rank hold HCA as of Q2 2026.
- Ballentine Partners held 3,670 shares of HCA Healthcare worth $1.43M as of Q2 2026.
- Ballentine Partners sold 49 HCA Healthcare shares in Q2 2026, an estimated $20.7K.
- HCA Healthcare made up 0.02% of Ballentine Partners's portfolio in Q2 2026, its #293 holding.
- Ballentine Partners first reported a position in HCA Healthcare in Q3 2018 and has held it in 31 quarters since.
- Ballentine Partners's HCA Healthcare position peaked at $1.76M in Q1 2026.
- 1,339 funds tracked by Wall St. Rank held HCA Healthcare as of Q2 2026.
Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.